| 英文摘要 |
Atomoxetine, a selective norepinephrine reuptake inhibitor, is the fi rst non-stimulant medication approved by the Food and Drug Administration of the United States (US FDA) for treatment in children with attention defi cit/hyperactivity disorder (ADHD) in 2002. The US FDA added a warning label to atomoxetine, indicating an increased risk for severe liver injury based on two post-market reports of atomoxetine-induced hepatitis. No acute liver event was reported in the clinical trial of atomoxetine in Taiwanese children and adolescents. Here, we report a case of acute hepatitis after a two-month use of atomoxetine in Taiwan. The 9-year-old Taiwanese girl patient was diagnosed as epilepsy at age of 9 months, autism spectrum disorder at 2 years, and ADHD at 9 years. Because of intolerable side effects of methylphenidate, she started to receive atomoxetine to treat her hyperactivity at 9 years, when she had been treated by levetiracetam 250 mg/day and phenobarbital 90 mg/day for epilepsy for years. Her mother reported that she had a mild elevated liver enzymes (alanine aminotransferase [ALT] 68 IU/L, aspartate aminotransferase [AST] 56 IU/L) after using phenobarbital 3 years ago, when the autoimmune survey (anti-nuclear antibody, C3 and C4) showed negative fi ndings. |
本站僅提供期刊文獻檢索。
